COVID-19 Vaccine Developers Adjust Phase 3 Trial Protocols to Allow Authorized Vaccines | 2020-12-17
The Pharma Data
DECEMBER 17, 2020
It’s going to change everyone’s behavior otherwise,” suggested Hayley Gans, a pediatrics and infectious diseases expert at Stanford University Medical Center. This would mean volunteers who already received a vaccine would be given a placebo and vice versa, allowing companies to evaluate their product’s safety and long-term efficacy.
Let's personalize your content